

CD262 (DR5) Monoclonal Antibody (DJR2-4 (7-8)), Biotin, eBioscience™

Product Details	
Size	100 µg
Species Reactivity	Human
Published Species	Human
Host/Isotype	Mouse / IgG1, kappa
Recommended Isotype Control	Mouse IgG1 kappa Isotype Control (P3.6.2.8.1), Biotin, eBioscience™
Class	Monoclonal
Type	Antibody
Clone	DJR2-4 (7-8)
Conjugate	Biotin
Form	Liquid
Concentration	0.5 mg/mL
Purification	Affinity chromatography
Storage buffer	PBS, pH 7.2, with 0.1% gelatin
Contains	0.09% sodium azide
Storage conditions	4° C, store in dark, DO NOT FREEZE!
RRID	AB_466975

Applications	Tested Dilution	Publications
Western Blot (WB)	-	2 Publications
Immunocytochemistry (ICC/IF)	-	1 Publication
Flow Cytometry (Flow)	0.5 µg/test	10 Publications
Radioimmune Assays (RIA)	-	1 Publication

Product Specific Information


Description: The DJR2-4 monoclonal antibody reacts with human DR5, also known as TRAIL-R2, Apo2, TRICK2 and KILLER. DR5 binds to TRAIL, activates NF-kappaB, and induces TRAIL-mediated apoptosis. DR5 is expressed broadly by normal tissues as well as several tumor cells.

Applications Reported: The DJR2-4 (a.k.a. 7-8) antibody has been reported for use in flow cytometric analysis.

Applications Tested: The DJR2-4 (a.k.a. 7-8) antibody has been tested by flow cytometric analysis of human MOLT-4 cell line and human DR5-transfected cells. This can be used at less than or equal to 0.5 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10⁵ to 10⁸ cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.


Filtration: 0.2 µm post-manufacturing filtered.

Advanced Verification Data



CD262 (DR5) Antibody (13-9908-82)

Figure 3 2DG increases DR5 expression levels with no effect on DR4, however, the increase in TRAIL-induced apoptosis requires additional mechanisms. (a) QRT-PCR of DR4 and DR5 transcripts in HT29 cells with and without 2DG treatment. (b) Immunoblotting for DR4 and DR5 indicated increased DR5 protein expression with 2DG treatment. (c) DR surface expression in various TRAIL resistant colon, gastric and pancreatic adenocarcinoma cells. (d) DR5 surface expression increases with 2DG treatment over time in HT-29 cells. (e) Apoptosis, as assessed by caspase-3 activation, in the same group of HT-29 cells increased over a 24 h time course upon treatment with 2DG+TRAIL, corresponding temporally with the increase in DR5 expression. (f) To knock down DR5 expression, HT-29 cells were transduced with the indicated lentiviral constructs and allowed to grow for 48 h. A lentivirus expressing a scrambled sequence was used as a control. (g) Cell death was significantly decreased with DR5 knockdown in 2DG+TRAIL-treated cells, however, remained significantly higher than wild-type cells treated with 2DG or TRAIL alone. n =3, ** indicates P <0.01, ns indicates P >0.05. Cell treatment validation info.



CD262 (DR5) Antibody (13-9908-82) in Flow

Staining of human DR5 transfected cells with Anti-Human CD262 (DR5) PE. Appropriate isotype controls were used (open histogram). Total viable cells were used for analysis.

[View more figures on thermofisher.com](http://thermofisher.com)

14 References

Western Blot (2)

Cell death & disease

YIPF2 promotes chemotherapeutic agent-mediated apoptosis via enhancing TNFRSF10B recycling to plasma membrane in non-small cell lung cancer cells.

"Published figure using CD262 (DR5) monoclonal antibody (Product # 13-9908-82) in Flow Cytometry"

Authors: Wang Y,Guo S,Li D,Tang Y,Li L,Su L,Liu X

Species

Not Applicable

Dilution

Not Cited

Year

2020

Cell death discovery

Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis.

"13-9908 was used in Flow cytometry/Cell sorting to investigate mechanisms to alter glucose metabolism in order to selectively target the cancer cells and to overcome evasion of apoptosis."

Authors: Carr RM,Qiao G,Qin J,Jayaraman S,Prabhakar BS,Maker AV

Species

Human

Dilution

Not Cited

Year

2016

Immunocytochemistry (1)

PLoS one

TRAIL-mediated apoptosis in breast cancer cells cultured as 3D spheroids.

"Published figure using CD262 (DR5) monoclonal antibody (Product # 13-9908-82) in Immunofluorescence"

Authors: Chandrasekaran S,Marshall JR,Messing JA,Hsu JW,King MR

Species

Not Applicable

Dilution

Not Cited

Year

2015

Flow Cytometry (10)

Scientific reports

Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas.

"Published figure using CD262 (DR5) monoclonal antibody (Product # 13-9908-82) in Flow Cytometry"

Authors: An Y,Jeon J,Sun L,Derakhshan A,Chen J,Carlson S,Cheng H,Silvin C,Yang X,Van Waes C,Chen Z

Species

Not Applicable

Dilution

Not Cited

Year

2021

[View more Flow references on thermofisher.com](#)

More applications with references on thermofisher.com

RIA (1)

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization. Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample. NO OTHER WARRANTIES, EXPRESS OR IMPLIED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT. BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPAIR, REPLACEMENT OF OR REFUND FOR THE NON-CONFORMING PRODUCT(S) AT SELLER'S SOLE OPTION. THERE IS NO OBLIGATION TO REPAIR, REPLACE OR REFUND FOR PRODUCTS AS THE RESULT OF (I) ACCIDENT, DISASTER OR EVENT OF FORCE MAJEURE, (II) MISUSE, FAULT OR NEGLIGENCE OF OR BY BUYER, (III) USE OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS. Unless otherwise expressly stated on the Product or in the documentation accompanying the Product, the Product is intended for research only and is not to be used for any other purpose, including without limitation, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses, or any type of consumption by or application to human or animals.